Scholars@Duke publication: Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CART-cell Therapy, in US Adults with B-ALL

Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CART-cell Therapy, in US Adults with B-ALL

Conferences

Leblanc, TW; Bertwistle, D; Joshi, P; Patel, D; Huggar, D

Published in: TRANSPLANTATION AND CELLULAR THERAPY

February 2026

Link to item

Duke Scholars

Author Thomas William LeBlanc Medicine, Hematologic Malignancies and Cellular Therapy

Altmetric Attention Stats

Dimensions Citation Stats

Published In

TRANSPLANTATION AND CELLULAR THERAPY

EISSN

2666-6367

ISSN

2666-6375

Publication Date

February 2026

Volume

Issue

Start / End Page

S114 / S113

Related Subject Headings

Immunology
3201 Cardiovascular medicine and haematology

Citation

APA

Chicago

ICMJE

MLA

NLM

Leblanc, T. W., Bertwistle, D., Joshi, P., Patel, D., & Huggar, D. (2026). Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CART-cell Therapy, in US Adults with B-ALL. In TRANSPLANTATION AND CELLULAR THERAPY (Vol. 32, pp. S114–S113).

Leblanc, Thomas W., David Bertwistle, Prashant Joshi, Dilip Patel, and David Huggar. “Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CART-cell Therapy, in US Adults with B-ALL.” In TRANSPLANTATION AND CELLULAR THERAPY, 32:S114–S113, 2026.

Leblanc TW, Bertwistle D, Joshi P, Patel D, Huggar D. Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CART-cell Therapy, in US Adults with B-ALL. In: TRANSPLANTATION AND CELLULAR THERAPY. 2026. p. S114–S113.

Leblanc, Thomas W., et al. “Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CART-cell Therapy, in US Adults with B-ALL.” TRANSPLANTATION AND CELLULAR THERAPY, vol. 32, no. 2, 2026, pp. S114–S113.

Leblanc TW, Bertwistle D, Joshi P, Patel D, Huggar D. Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CART-cell Therapy, in US Adults with B-ALL. TRANSPLANTATION AND CELLULAR THERAPY. 2026. p. S114–S113.

Published In

TRANSPLANTATION AND CELLULAR THERAPY

EISSN

2666-6367

ISSN

2666-6375

Publication Date

February 2026

Volume

Issue

Start / End Page

S114 / S113

Related Subject Headings

Immunology
3201 Cardiovascular medicine and haematology